Loading
HPK1 is a brake inside immune cells: it dampens a T cell's response once the cell has recognised its target. Blocking it is meant to let T cells attack a tumour harder, and an HPK1 inhibitor is in an early trial, alone and with a checkpoint antibody. This dossier gathers the 1 product (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Hematopoietic cell-restricted MAP4K family serine/threonine kinase; a negative regulator of T-cell receptor signalling in the cited mouse studies, so inhibition is an immune-activating rather than a tumour-cell-killing strategy.
| Modality | Phase 1 |
|---|---|
| Small molecule 1 |
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"HPK1" OR ABSTRACT:"HPK1" OR TITLE:"MAP4K1" OR ABSTRACT:"MAP4K1" OR TITLE:"hematopoietic progenitor kinase 1" OR ABSTRACT:"hematopoietic progenitor kinase 1" OR TITLE:"mitogen-activated protein kinase kinase kinase kinase 1" OR ABSTRACT:"mitogen-activated protein kinase kinase kinase kinase 1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HPK1 (MAP4K1), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/hpk1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/hpk1.json. Licence CC BY-NC 4.0.